ERBB2 and breast cancer: Importantly, a large pooled analysis of 3,771 patients by Denkert et al. demonstrated that higher concentrations of TILs predicted a greater likelihood of pCR and longer survival in TNBC and HER2-positive breast cancers, while paradoxically serving as an adverse prognostic indicator in luminal-HER2-negative subtypes [15].